Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
Innovent Biologics and Eli Lilly have signed a commercialization agreement for the cancer drug Verzenios in mainland China. Under the deal, Innovent will manage distribution and promotion, while Lilly retains manufacturing responsibilities.
Why it matters
This partnership expands access to advanced oncology treatments in the Chinese market, leveraging local commercial expertise for global pharmaceutical products.
SAN FRANCISCO and SUZHOU, China , June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, and Eli Lilly and Company (NYSE: LLY ) today jointly announced that they have entered into a distribution and promotion agreement regarding Lilly's CDK4 & 6 inhibitor Verzenios ® (abemaciclib) in mainland China:
The content is a standard corporate press release regarding a business partnership.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in